Innovative drug discovery information platform 'Design Hub'

Patcore Inc. (Headquarters: Tokyo) has partnered with Chemical.AI (USA/China), a global leader in AI technology for chemical synthesis route design, to begin domestic provision of the AI retro-synthesis platform "ChemAIRS." ChemAIRS is a platform where AI, equivalent to skilled chemists with over 10 years of experience, can automatically propose complex synthesis routes in just a few minutes. It enables the identification of chirality introduction risks, prediction of side reactions and impurities, and the design of highly feasible routes considering raw material availability, yield, and cost. Additionally, it seamlessly integrates with Chemaxon's "Design Hub," for which Patcore serves as the exclusive domestic distributor, accelerating the DMTA cycle in a one-stop manner. Currently, we are accepting applications for a two-week free trial. For more details about the product and to apply, please contact us through Patcore Inc.'s official website. ▶ Two-week free trial now available Try out its capabilities with the challenges in your research lab. ▼ ChemAIRS product page: https://patcore.com/product/chemairs

Chemical.AI, a global leader in artificial intelligence (AI) for synthetic route design and prediction, and Chemaxon, a leading company in chemical and biological software development, have announced a strategic partnership that will allow access to Chemical.AI's reverse synthesis tool, ChemAIRS, as an option from Chemaxon's drug discovery platform, Design Hub. This collaboration creates compatibility between Chemical.AI's ChemAIRS and Chemaxon's Design Hub, enabling a seamless user workflow and one-stop service that integrates compound design tracking and prioritization features from Design Hub with the innovative synthetic routes generated in minutes using ChemAIRS's diverse strategies. For more details, please visit our website.

Chemaxon, a leader in the development of cheminformatics software for life sciences research, has announced the appointment of Richard Jones as Chief Executive Officer (CEO). Richard succeeds the owner, Ferenc (Csizi) Csizmadia, in this role. Csizi will continue to serve as a founder while focusing on the establishment of Ancestralize, which is centered on health and well-being in the digital age. Additionally, coinciding with Mr. Richard's appointment, Chemaxon's Budapest office has relocated to the newly constructed environmentally friendly office park, Váci Greens, on the east side of the Danube River. A new logo and spelling have also been announced. For more details, please visit the news article on our company's homepage via the link below.

"Can even new drugs be discovered from commercially available compounds?" The size of the drug-like chemical space is estimated to be about 10^63 molecules. It is expected that future drugs will be found somewhere in this vast space. To enable chemists to easily access this chemical space, several compound vendors are building commercial databases of available compounds or drug-like compounds that are predicted to have a high likelihood of being synthesized. Many pharmaceutical companies are also building their own databases. ChemAxon provides access to various databases through its compound design platform "Design Hub," and we have compiled this information into a white paper, so please take a look.